Pharm Exec1d
Biogen Seeks FDA Approval for a Higher Dosing Regimen of Spinraza for Spinal Muscular Atrophy
Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...
Pharm Exec1d
AbbVie, Neomorph Strike Deal to Co-Develop Molecular Glue Degraders for Oncology, Immunology
Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...
Pharm Exec1d
Using Digital Therapeutics with Abuse-Deterrent Pain Medication
Paul Howe, chief commercial officer at Protega, discusses efforts to combine high tech solutions with pain-management medications.
Pharm Exec2d
FDA Approves Two Generics from Amneal Pharmaceuticals for Alzheimer and Oncology, with Tentative Approval for Gastrointestinal Disease
As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in ...
Pharm Exec2d
Viralgen and Axovia Partner to Manufacture Gene Therapy for Retinal Dystrophy in Bardet-Biedl Syndrome Patients
Viralgen and Axovia Therapeutics are partnering to develop and manufacture a gene therapy for the treatment of retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS) caused by biallelic ...
Pharm Exec2d
Arvinas Announces Interim Chief Commercial Officer
Arvinas, Inc, announced that its chief commercial officer, John Northcott, is stepping down as of mid-January. 1 While the ...
Pharm Exec2d
The Ups and Downs of AI for Pharma Investors
Ash Shehata from KPMG discusses how artificial technology has a lot to prove, although investors still see a lot of potential in it.
Pharm Exec3d
Jelmyto Demonstrates Significant Recurrence-Free Survival Rate at Three Years in Patients with Low-Grade Upper Tract Urothelial Cancer
Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with Jelmyto. A majority of patients with low-grade upper tract urothelial ...